Linkedin Twitter Envelope

News

Home
/
/
OTCA21 ‘Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea’ Final Assessment now available

OTCA21 ‘Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea’ Final Assessment now available

EUnetHTA is pleased to announce that the OTCA21 Final Assessment is now available for access.

The assessed technology is Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea. The aim of this assessment was to evaluate effectiveness and safety of HGNS compared with no treatment in those adult patients with moderate-to-severe obstructive sleep apnea (OSA) who present inadequate adherence to positive airway pressure systems or to other non-invasive procedures.

OTCA21 – Final Assessment Report

OTCA21 – External Review by Experts and Fact-Check by Manufacturers

OTCA21 – Final Project Plan

OTCA21 – Plain Language Summary

OTCA21 – Comments from external experts and manufacturers including author replies

More news

OUR NETWORK

CAREERS

HELP

eunethta@zinl.nl

CONTACT US

This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.

©2021 EUnetHTA All rights reserved.

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.
Accept and Close